Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: A phase I clinical trial

Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efcacy of combination treatment with osimertinib and afatinib for patients with acquired resistance to osimertinib.